Bio-Techne Corp. (TECH) Financial Statements
Historical financial data — 44 statements covering FY2016–FY2026
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein s...
Bio-Techne Corp.'s revenue decreased 0.4% year over year, from $1.22B to $1.22B.
Net income increased 147.8% over the same period, from $73.4M to $181.9M.
Over the 10-year period from FY2016 to FY2026, revenue grew by 143% in total.
Total debt decreased by 16.4% to $289.1M.
The debt-to-equity ratio stands at 0.14, indicating a conservative leverage profile.
Operating cash flow grew 1.6% to $292.1M.
Bio-Techne Corp. maintains a healthy net profit margin of 15.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2025 | $289.5M-5.4% | $33.6M | $183.0M | $40.0M | $63.9M | $2.74B | $300.0M | $2.14B |
| Q2 FY2025 | $297.0M+2.6% | $34.9M | $193.9M | $47.4M | $84.3M | $2.67B | $300.0M | $2.08B |
| Q3 FY2025 | $316.2M+6.4% | $22.6M | $214.6M | $38.7M | $41.1M | $2.64B | $330.0M | $2.02B |
| Q4 FY2025 | $317.0M+0.2% | $-17.7M | $198.8M | $97.3M | $98.2M | $2.56B | $346.0M | $1.92B |
| Q1 FY2026 | $286.6M-9.6% | $38.2M | $188.1M | $47.7M | $27.6M | $2.53B | $300.0M | $1.97B |
| Q2 FY2026 | $295.9M+3.3% | $38.0M | $191.3M | $54.5M | $82.4M | $2.52B | $260.0M | $2.01B |
| Q3 FY2026 | $311.4M+5.3% | $51.0M | $208.3M | $75.5M | $86.7M | $2.55B | $290.3M | $2.09B |
| Q4 FY2026 | $321.2M+3.1% | $54.6M | $211.4M | $74.3M | $95.4M | $2.59B | $289.1M | $2.11B |
Balance Sheet Summary (FY2026)
Bio-Techne Corp. (TECH) Financial Statements & Revenue History
Bio-Techne Corp. (TECH) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry trading at $72.57 with a market capitalization of $11. This page provides 44 historical financial statements for Bio-Techne Corp., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Bio-Techne Corp. reported revenue of $1.2 billion, a 0.4% decline from the prior year. The net profit margin of 15.0% indicates moderate profitability. The debt-to-equity ratio of 0.14 shows conservative leverage.
TECH Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Bio-Techne Corp.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether TECH is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track TECH's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Bio-Techne Corp. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of TECH's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use TECH Financial Data
Investors use Bio-Techne Corp.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare TECH's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how TECH's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View TECH's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Bio-Techne Corp.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.TECH trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.